Why sclerostin became the dominant anabolic target in osteoporosis

Sclerostin (SOST) is a secreted glycoprotein produced by osteocytes that suppresses osteoblast activity by antagonizing WNT/LRP5/LRP6 co-receptor signaling — and inhibiting it produces a dual anabolic-anticatabolic effect that no prior osteoporosis therapy has matched. In retrieved patent filings from Amgen Inc., Novartis AG, UCB Pharma, Celltech R&D, and Mereo BioPharma 3 Limited, sclerostin is uniformly characterized as a TGF-β superfamily–related protein whose inhibition simultaneously elevates bone formation markers (BSAP, P1NP, osteocalcin) and reduces bone resorption markers (CTX, NTX).

The mechanistic logic is straightforward: in osteoporosis, bone remodeling is uncoupled — resorption exceeds formation, leading to net bone loss, elevated fracture risk, and the associated morbidity and mortality burden tracked by organizations including WHO and the International Osteoporosis Foundation. Bisphosphonates and denosumab address the resorption side; PTH analogs stimulate formation but cannot simultaneously suppress resorption. Anti-sclerostin antibodies do both.

The convergence of patent activity across multiple large-cap pharma and specialty biotech assignees around a single molecular target — sclerostin — reflects both the clinical validation of the WNT pathway in human bone biology and the commercial opportunity in a disease area where existing therapies leave significant unmet need in patients with severe or progressive bone loss. According to WIPO data on biologics patent filing trends, antibody-based bone therapeutics represent one of the most consistently active areas in musculoskeletal IP over the past decade.

The Celltech R&D filing from 2005 — now held by UCB Pharma — represents the foundational patent in this dataset, citing sclerostin’s relationship to the TGF-β superfamily and BMPs as the mechanistic basis for anti-sclerostin antibody use in increasing bone mineral content. The two decades of subsequent IP activity built on this foundation constitute one of the most intensively developed antibody target areas in musculoskeletal medicine.

The anti-sclerostin antibody IP landscape: Amgen, Novartis, and beyond

Amgen Inc. holds the broadest and most multi-jurisdictional anti-sclerostin patent portfolio in the retrieved dataset, with active or recently active filings across EP, ES, WO, CA, AU, HK, HU, and PT — covering methods for treating osteoporosis, inhibiting bone resorption, treating alveolar bone loss, and fracture healing via sclerostin binding agents. The clinical data embedded in these filings describes lumbar vertebral BMD increases of at least 9% from pretreatment baseline at 12 months in postmenopausal women with T-score ≤ −2, at monthly doses of 140–210 mg.

Novartis AG’s anti-sclerostin antibody MOR05813 binds sclerostin epitopes spanning amino acids 112–126 and 160–174 with affinities in the low picomolar range and an IC₅₀ of approximately 10 nM for inhibiting sclerostin’s effect on WNT signaling. In vivo data in aged rodents reported in Novartis EP filings show bone mass increases comparable to anabolic doses of PTH — a direct mechanistic benchmark against the existing standard of care. Novartis also discloses in vivo data showing combinatorial BMD enhancement when MOR05813 is co-administered with anti-DKK1 antibody or PTH in mouse models, providing proof-of-concept for dual WNT pathway activation strategies.

The most clinically advanced indication expansion in this dataset is Mereo BioPharma 3 Limited’s use of setrusumab in osteogenesis imperfecta (OI), a rare connective tissue disorder. The 2025 US patent filing references human OI patient clinical data showing continuous BMD improvement over monthly setrusumab dosing, with the notable finding that attenuation of bone turnover biomarkers does not translate to BMD attenuation — described in the filing as an unexpected and clinically significant result that informs dosing regimen design. This dissociation between biomarker and BMD response is strategically important: it suggests that standard biomarker-based endpoints may not fully capture the therapeutic benefit of anti-sclerostin antibodies in rare bone diseases.

“Inhibition of sclerostin simultaneously elevates bone formation markers and reduces bone resorption markers — a dual anabolic-anticatabolic profile that differentiates this modality from bisphosphonates or PTH analogs alone.”

UCB Pharma’s active JP patent on washout period strategies for anti-sclerostin antibody therapy signals IP activity in the post-approval optimization space — an increasingly important domain as the field moves from first-in-class approval toward label differentiation, dosing flexibility, and long-term management protocols. This mirrors patterns seen in other biologic therapeutic areas where method-of-treatment patents extend commercial protection well beyond composition-of-matter expiry.

Next-generation anabolic modalities: ActRII traps, PTH analogs, and small molecules

Beyond anti-sclerostin antibodies, the retrieved dataset identifies five distinct anabolic modality classes at varying stages of development — from approved PTH analogs to preclinical epigenetic agents. Together they represent the breadth of the bone anabolic pipeline and the range of IP strategies being deployed by pharma, biotech, and academic institutions.

Activin receptor II ligand traps

Keros Therapeutics, Inc. holds active and pending patents (IL, JP) on extracellular ActRIIA and ActRIIB chimeric polypeptides fused to Fc domains. These engineered ligand traps bind and sequester activin A, activin B, myostatin, and BMP9, thereby increasing bone formation, bone strength, and reducing fracture risk. A key differentiating feature of the Keros approach — described explicitly in the filings — is selectivity engineering to avoid BMP inhibition, which would impair bone formation, while capturing activin A/B and myostatin. Claimed indications include primary and secondary osteoporosis, osteopenia, Paget’s disease, and osteogenesis imperfecta.

Acceleron Pharma Inc. (now Merck) holds active HK patents on soluble ActRIIa-Fc polypeptides that promote bone growth and density by inhibiting the activin–ActRIIa signaling axis, with an explicit claim in the CN filing for treatment of osteoporosis and fracture healing. The filings note a potentially favorable musculoskeletal selectivity profile — promoting bone density without causing sustained muscle mass increases. Keros Therapeutics filings additionally describe ActRII chimeras as candidates for concurrent treatment of bone loss and muscle atrophy, positioning this platform as a dual anabolic agent relevant in sarcopenic osteoporosis.

PTH and PTHrP receptor agonists

Teriparatide (PTH 1-34) remains the benchmark first-approved anabolic agent referenced across multiple records in this dataset. Asahi Kasei Pharma discloses once-weekly PTH dosing at 100–200 IU with superior safety and comparable efficacy to daily regimens, citing ASBMR and IOF World Congress abstracts on 18-month ovariectomized monkey studies. Radius Health’s JP filing describes abaloparatide (PTHrP analog, SEQ ID NO: 1) administered subcutaneously at 80 μg, reducing non-vertebral fractures at wrist and hip in postmenopausal women — including those with type 2 diabetes and high cortical bone porosity, a specific patient subgroup for which additional fracture prevention options are needed. Eli Lilly holds CN filings on PEGylated PTH compositions as PTH receptor modulators for treating bone loss including osteoporosis.

Anti-resorptive antibodies: RANKL and Siglec-15

Amgen’s legacy anti-OPGL (RANKL) antibody patents describe the mechanistic basis for denosumab — inhibiting osteoclast differentiation induced by OPGL-ODAR coupling. More strategically novel is Daiichi Sankyo Company’s anti-Siglec-15 program: Siglec-15 is an osteoclast-expressed sialic acid-binding lectin whose gene expression increases during osteoclast differentiation and maturation. Anti-Siglec-15 antibodies suppress TRAP-positive multinucleated osteoclast formation and lacunar bone resorption activity in vitro, with animal model validation in ovariectomized rats and monkeys across EP, ES, JP, HK, and CN filings. Daiichi Sankyo’s filings consistently position Siglec-15 as a target orthogonal to RANKL, potentially enabling bone resorption suppression in patients who have developed resistance or intolerance to anti-RANKL therapy.

Small molecules and epigenetic agents

Several preclinical approaches are represented in the dataset. Chongqing Medical University’s 2023 CN filing discloses compound C91, a GSK-3β inhibitor that activates canonical WNT signaling in ST2 stromal cells, upregulating osteoblast marker genes (Alpl, Bglap, Runx2, Sp7) and promoting bone nodule formation, with autophagy implicated in the mechanism. Mayo Foundation filings claim EZH2 polypeptide inhibitors (GSK126, UNC1999) and sulforaphane for fracture healing, implant ingrowth, and joint fusions. Massachusetts General Hospital describes HDAC6-selective inhibitors that simultaneously inhibit osteoclastogenesis and activate osteoblast formation — a dual anabolic-anticatabolic mechanism distinct from pan-HDAC inhibitors. UWM Research Foundation’s 2023–2025 WO and US filings claim p21 (CDKN1A) suppression in mesenchymal stem cells to increase osteogenic capacity and reduce adipogenic differentiation in aged and diabetic subjects — addressing populations underserved by current anabolic agents.

An entirely distinct upstream approach comes from the Board of Regents, University of Texas System (WO, 2024): antibodies binding connexin 43 (Cx43) hemichannels in osteocytes to activate channel opening, thereby suppressing sclerostin expression endogenously and increasing prostaglandin E2 release, inhibiting osteocyte apoptosis, and promoting fracture healing. This positions Cx43 as an upstream regulator of the SOST-WNT axis — a potential route to sclerostin suppression with different tissue distribution and pharmacokinetic properties compared to systemic anti-sclerostin antibodies.

Combination and sequential therapy: the emerging IP battleground

Combination and sequential therapy protocols are increasingly being claimed at the IP level, creating a contested space where overlapping mechanistic rationale across assignees may generate freedom-to-operate challenges. The most clearly defined combination strategy in this dataset is the anabolic-then-antiresorptive sequence — using a bone-forming agent to build bone mass, then switching to an antiresorptive to preserve the gain.

Novartis EP and BR filings include in vivo mouse pQCT data showing that co-treatment of MOR05813 with zoledronic acid, or sequential treatment following alendronate pre-treatment, affects total BMD, bone mineral content, cortical thickness, and cancellous BMD — providing IP-level claim coverage for combination strategies that mirror the clinical transition approach used in practice. The same Novartis filing covers co-treatment with anti-DKK1 antibody or PTH, providing proof-of-concept for dual WNT pathway activation combining anti-sclerostin and anti-DKK1 mechanisms at different nodes of the same pathway.

Radius Health’s JP filing explicitly includes a claim for co-administering a bone resorption inhibitor with the PTHrP analog abaloparatide — consistent with the sequential anabolic-then-antiresorptive clinical paradigm and extending IP coverage into combination use. The University of Texas System’s 2024 Cx43 hemichannel antibody filing introduces a conceptually distinct combination rationale: upstream SOST transcription suppression via Cx43 activation could be combined with direct anti-sclerostin antibodies for additive pathway suppression, or used as a monotherapy with a different safety and PK profile.

Keros Therapeutics’ ActRII chimera filings describe a dual anabolic indication — concurrent treatment of bone loss and muscle atrophy — that is particularly relevant in sarcopenic osteoporosis, a condition increasingly recognized by NIH and geriatric medicine bodies as a major contributor to fracture risk and functional decline in elderly populations. This dual-indication positioning represents a differentiated commercial strategy compared to bone-only anabolic agents.

The miRNA approach from Kawasaki University School of Medicine — identifying miR-140-3p as a bone-forming regulator linking TGF-β3 to the WNT pathway and directly promoting osteocalcin expression — represents an early-stage but mechanistically distinct modality that could complement protein-based anabolic agents. The filing proposes miR-140-3p as both a therapeutic agent and a biomarker for osteoporosis treatment monitoring, a dual utility that aligns with the broader trend toward companion diagnostics in specialty bone diseases.

Strategic implications for drug developers and IP teams

The patent landscape for bone anabolic agents is stratified into three tiers of commercial maturity — and understanding where each modality sits determines the appropriate IP, development, and licensing strategy.

Sclerostin inhibition remains the most IP-dense anabolic mechanism in this dataset, with Amgen holding the broadest multi-jurisdictional portfolio. However, active filings from Novartis, UCB, and Mereo BioPharma signal a competitive and expanding IP landscape, particularly in dosing optimization, washout strategy, and rare disease extensions such as osteogenesis imperfecta — areas where differentiated label claims may provide commercial runway beyond primary osteoporosis. Indication expansion beyond postmenopausal osteoporosis is a key strategic direction: retrieved results cover alveolar bone loss (Amgen), osteogenesis imperfecta (Mereo), and fracture healing, each representing orphan or specialty segments with potentially favorable regulatory pathways.

The activin/ActRII ligand trap platform (Keros Therapeutics, Acceleron/Merck) represents the most patent-active next-generation anabolic class in this dataset after anti-sclerostin antibodies, with pending patent status indicating active commercial development. Small-molecule WNT pathway agonists (GSK-3β inhibitors, oxysterols) and epigenetic agents (EZH2 inhibitors, HDAC6 inhibitors, p21 suppressors) are preclinically active but remain IP-stage innovations without clinical signals in this dataset — representing potential best-in-class or next-generation oral anabolic agent opportunities if translational challenges of selectivity, bone-tissue targeting, and chronic safety can be addressed.

For IP strategists, the most immediate risk areas are method-of-treatment claims covering combination and sequential therapy protocols. As the European Patent Office and USPTO continue to grant second medical use claims for established biologics in new indications or dosing regimens, the overlap between assignees’ combination claims — particularly around the anabolic-then-antiresorptive sequence and dual WNT pathway activation — creates a landscape that requires active freedom-to-operate monitoring. The Siglec-15 program from Daiichi Sankyo represents a strategically distinct anti-resorptive position orthogonal to RANKL, potentially offering a differentiated commercial profile in patients with RANKL resistance or intolerance — a population whose size and clinical characteristics are being actively studied in bone biology research tracked by bodies including the International Osteoporosis Foundation.

The p21/MSC biology approach from UWM Research Foundation introduces a conceptually distinct anabolic strategy: targeting senescence-associated cell-cycle regulators in mesenchymal stem cells to restore osteogenic capacity in aged, diabetic, or immobilized patients. This addresses a population underserved by current anabolic agents and aligns with the broader trend in geroscience toward targeting cellular senescence as a root cause of age-related tissue dysfunction — a research direction increasingly supported by academic and government funding agencies. Developers tracking the osteoporosis pipeline should monitor this space as it moves from preclinical to IND-enabling studies.

PatSnap’s innovation intelligence platform provides pharmaceutical and biotech teams with the tools to map assignee portfolios, track pending claims, and identify white space in the bone anabolic IP landscape. The PatSnap Eureka AI research assistant enables rapid synthesis of patent and literature signals across this complex multi-target, multi-modality field.